Statins and Mortality of Patients After Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis Publisher Pubmed



Yarahmadi P¹ ; Kabiri A² ; Forouzannia SM¹ ; Yousefifard M³ Show Affiliations
Source: Angiology Published:2023

Abstract

While TAVI is widely used, optimal medical therapy to reduce the mortality rate after transcatheter aortic valve implantation (TAVI) is still unclear. We performed a systematic review and meta-analysis to evaluate the impact of statins on mortality following TAVI. Present systematic review of the literature was performed using Medline, Embase, Scopus, and Web of Science; all studies reported all-cause mortality in patients who underwent TAVI and received or did not receive statin therapy. Data were analyzed using random-effects models. Seventeen articles (21 380 patients) were included in the meta-analysis. Statin therapy was associated with a reduction of all-cause mortality (Hazard ratio [HR] =.78, 95% Confidence interval [CI].68–.89, P <.001). Moderate between-study heterogeneity was observed (I2 = 45.2). High-intensity statin therapy was more effective than low or moderate intensity statin therapy in reduction of all-cause mortality (Risk ratio [RR] =.62, 95% CI 0.45–.85, P =.003, I2 =.0). Statin therapy could reduce the mid-term all-cause mortality rate following TAVI. However, all included studies were observational and, therefore, randomized controlled trials are still needed to assess the effect of statin therapy on mortality after TAVI. © The Author(s) 2022.